Less than two hundred years ago schizophrenia emerged from a tangle of mental disorders known simply as madness. Today its diagnosis remains shrouded...
A recent article featuring Myriad RBM's services was published in PLoS ONE by a group of researchers investigating the differences in biomarker profil...
As a major participant in the largest protein biomarker study of its kind, Myriad RBM will analyze more than 8,000 samples for Sanofi Aventis' Outcome...
Dr. Ivan O Rosas, a faculty member in the Division of Pulmonary and Critical Care, Department of Medicine, Brigham and Women's Hospital, Harvard Medic...
Today, nearly every drug development program has a biomarker discovery project with which it is associated. In just the last five years, this has beco...
Leading researchers are a step closer to developing a blood test for Alzheimer's using a targeted proteomics approach enabled by Myriad RBM's Discover...
In this paper, published in the Journal of Biological Chemistry, researchers used Myriad RBM's services to discover a cytokine signature that was indi...